{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(5)"],"submitter":["Liu J"],"pubmed_abstract":["<h4>Introduction</h4>The approximately 70% 12-month relapse in children experiencing the initial episode of steroid-sensitive nephrotic syndrome (SSNS) is a significant concern, with over 50% developing frequent relapses or steroid-dependent nephrotic syndrome (FRNS/SDNS). There is a lack of strategies to reduce relapse after the onset. Whether early administration of rituximab, which effectively reduces relapses in FRNS/SDNS, may be a solution has not been evaluated.<h4>Methods</h4>A prospective, multicenter, open-label, single-arm trial was conducted in China, with a 12-month follow-up. Children aged 1 to 18 years with the first episode of nephrotic syndrome (NS) were screened for eligibility. Proteinuria was evaluated daily using dipsticks. A dose of 375 mg/m<sup>2</sup> of rituximab wa"],"journal":["Kidney international reports"],"pagination":["1220-1227"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11069012"],"repository":["biostudies-literature"],"pubmed_title":["Early Rituximab as an Add-On Therapy in Children With the Initial Episode of Nephrotic Syndrome."],"pmcid":["PMC11069012"],"pubmed_authors":["Liu J","Shen Q","Xie L","Qian B","Deng F","Xu H","Zhang R","Yan W","Dou Y","Zhang Y","Sun S","Jiang X","Wang X","Liu C","Zhang A"],"additional_accession":[]},"is_claimable":false,"name":"Early Rituximab as an Add-On Therapy in Children With the Initial Episode of Nephrotic Syndrome.","description":"<h4>Introduction</h4>The approximately 70% 12-month relapse in children experiencing the initial episode of steroid-sensitive nephrotic syndrome (SSNS) is a significant concern, with over 50% developing frequent relapses or steroid-dependent nephrotic syndrome (FRNS/SDNS). There is a lack of strategies to reduce relapse after the onset. Whether early administration of rituximab, which effectively reduces relapses in FRNS/SDNS, may be a solution has not been evaluated.<h4>Methods</h4>A prospective, multicenter, open-label, single-arm trial was conducted in China, with a 12-month follow-up. Children aged 1 to 18 years with the first episode of nephrotic syndrome (NS) were screened for eligibility. Proteinuria was evaluated daily using dipsticks. A dose of 375 mg/m<sup>2</sup> of rituximab wa","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-06-03T05:07:55.524Z","creation":"2026-04-24T03:14:46.056Z"},"accession":"S-EPMC11069012","cross_references":{"pubmed":["38707815"],"doi":["10.1016/j.ekir.2024.02.1395"]}}